Volkan Korten1, Deniz Gökengin2, Gülhan Eren3, Taner Yıldırmak4, Serap Gencer5, Haluk Eraksoy6, Dilara Inan7, Figen Kaptan8, Başak Dokuzoğuz9, Ilkay Karaoğlan10, Ayşe Willke11, Mehmet Gönen12, Önder Ergönül13. 1. Department of Infectious Diseases and Clinical Microbiology, Marmara University, Istanbul, Turkey. korten@marmara.edu.tr. 2. Department of Infectious Diseases and Clinical Microbiology, Ege University, Izmir, Turkey. 3. Infectious Diseases Clinic, Istanbul Training and Research Hospital, Istanbul, Turkey. 4. Infectious Diseases Clinic, Okmeydanı Training and Research Hospital, Istanbul, Turkey. 5. Infectious Diseases Clinic, Lütfi Kirdar Training and Research Hospital, Istanbul, Turkey. 6. Department of Infectious Diseases and Clinical Microbiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey. 7. Department of Infectious Diseases and Clinical Microbiology, Akdeniz University, Antalya, Turkey. 8. Department of Infectious Diseases and Clinical Microbiology, Izmir Katip Çelebi University, Izmir, Turkey. 9. Infectious Diseases Clinic, Ankara Numune Training and Research Hospital, Ankara, Turkey. 10. Department of Infectious Diseases and Clinical Microbiology, Gaziantep University, Gaziantep, Turkey. 11. Infectious Diseases Clinic, Kent University Academic Hospital, Istanbul, Turkey. 12. College of Engineering and School of Medicine, Koç University, Istanbul, Turkey. 13. Department of Infectious Diseases and Clinical Microbiology, Koç University, Istanbul, Turkey.
Abstract
BACKGROUND: There is limited evidence on the modification or stopping of antiretroviral therapy (ART) regimens, including novel antiretroviral drugs. The aim of this study was to evaluate the discontinuation of first ART before and after the availability of better tolerated and less complex regimens by comparing the frequency, reasons and associations with patient characteristics. METHODS: A total of 3019 ART-naive patients registered in the HIV-TR cohort who started ART between Jan 2011 and Feb 2017 were studied. Only the first modification within the first year of treatment for each patient was included in the analyses. Reasons were classified as listed in the coded form in the web-based database. Cumulative incidences were analysed using competing risk function and factors associated with discontinuation of the ART regimen were examined using Cox proportional hazards models and Fine-Gray competing risk regression models. RESULTS: The initial ART regimen was discontinued in 351 out of 3019 eligible patients (11.6%) within the first year. The main reason for discontinuation was intolerance/toxicity (45.0%), followed by treatment simplification (9.7%), patient willingness (7.4%), poor compliance (7.1%), prevention of future toxicities (6.0%), virologic failure (5.4%), and provider preference (5.4%). Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (aHR = 4.4, [95% CI 3.0-6.4]; p < 0.0001) or protease inhibitor (PI)-based regimens (aHR = 4.3, [95% CI 3.1-6.0]; p < 0.0001) relative to integrase strand transfer inhibitor (InSTI)-based regimens were significantly associated with ART discontinuation. ART initiated at a later period (2015-Feb 2017) (aHR = 0.6, [95% CI 0.4-0.9]; p < 0.0001) was less likely to be discontinued. A lower rate of treatment discontinuation for intolerance/toxicity was observed with InSTI-based regimens (2.0%) than with NNRTI- (6.6%) and PI-based regimens (7.5%) (p < 0.001). The percentage of patients who achieved HIV RNA < 200 copies/mL within 12 months of ART initiation was 91% in the ART discontinued group vs. 94% in the continued group (p > 0.05). CONCLUSION: ART discontinuation due to intolerance/toxicity and virologic failure decreased over time. InSTI-based regimens were less likely to be discontinued than PI- and NNRTI-based ART.
BACKGROUND: There is limited evidence on the modification or stopping of antiretroviral therapy (ART) regimens, including novel antiretroviral drugs. The aim of this study was to evaluate the discontinuation of first ART before and after the availability of better tolerated and less complex regimens by comparing the frequency, reasons and associations with patient characteristics. METHODS: A total of 3019 ART-naive patients registered in the HIV-TR cohort who started ART between Jan 2011 and Feb 2017 were studied. Only the first modification within the first year of treatment for each patient was included in the analyses. Reasons were classified as listed in the coded form in the web-based database. Cumulative incidences were analysed using competing risk function and factors associated with discontinuation of the ART regimen were examined using Cox proportional hazards models and Fine-Gray competing risk regression models. RESULTS: The initial ART regimen was discontinued in 351 out of 3019 eligible patients (11.6%) within the first year. The main reason for discontinuation was intolerance/toxicity (45.0%), followed by treatment simplification (9.7%), patient willingness (7.4%), poor compliance (7.1%), prevention of future toxicities (6.0%), virologic failure (5.4%), and provider preference (5.4%). Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (aHR = 4.4, [95% CI 3.0-6.4]; p < 0.0001) or protease inhibitor (PI)-based regimens (aHR = 4.3, [95% CI 3.1-6.0]; p < 0.0001) relative to integrase strand transfer inhibitor (InSTI)-based regimens were significantly associated with ART discontinuation. ART initiated at a later period (2015-Feb 2017) (aHR = 0.6, [95% CI 0.4-0.9]; p < 0.0001) was less likely to be discontinued. A lower rate of treatment discontinuation for intolerance/toxicity was observed with InSTI-based regimens (2.0%) than with NNRTI- (6.6%) and PI-based regimens (7.5%) (p < 0.001). The percentage of patients who achieved HIV RNA < 200 copies/mL within 12 months of ART initiation was 91% in the ART discontinued group vs. 94% in the continued group (p > 0.05). CONCLUSION:ART discontinuation due to intolerance/toxicity and virologic failure decreased over time. InSTI-based regimens were less likely to be discontinued than PI- and NNRTI-based ART.
Authors: Conar R O'Neil; Alexis K Palmer; Suzy Coulter; Nadia O'Brien; Anya Shen; Wendy Zhang; Julio S G Montaner; Robert S Hogg Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2012-02-07
Authors: A Mocroft; A N Phillips; V Soriano; J Rockstroh; A Blaxhult; C Katlama; A Boron-Kaczmarska; L Viksna; O Kirk; J D Lundgren Journal: AIDS Res Hum Retroviruses Date: 2005-09 Impact factor: 2.205
Authors: Markus Bickel; Christian Hoffmann; Eva Wolf; Axel Baumgarten; Christoph Wyen; Christoph D Spinner; Hans Jäger; Nils Postel; Stefan Esser; Markus Mueller; Albrecht Stoehr; Stefan Preis; Stephan Klauke; Knud Schewe Journal: Infection Date: 2020-05-11 Impact factor: 3.553
Authors: Melanie Stecher; Philipp Schommers; Christian Kollan; Matthias Stoll; Frieder Kuhlendahl; Hans-Jürgen Stellbrink; Jan-Christian Wasmuth; Christoph Stephan; Laura Hamacher; Clara Lehmann; Christoph Boesecke; Johannes Bogner; Stefan Esser; Carlos Fritzsche; Annette Haberl; Dirk Schürmann; Olaf Degen; Heinz-August Horst; Christian Hoffmann; Björn Jensen; Carolynne Schwarze-Zander; Martin Platten; Gerd Fätkenheuer; Daniel Schmidt; Barbara Gunsenheimer-Bartmeyer; Jörg Janne Vehreschild Journal: Infection Date: 2020-07-01 Impact factor: 3.553
Authors: Steve Kanters; Marco Vitoria; Meg Doherty; Maria Eugenia Socias; Nathan Ford; Jamie I Forrest; Evan Popoff; Nick Bansback; Sabin Nsanzimana; Kristian Thorlund; Edward J Mills Journal: Lancet HIV Date: 2016-09-06 Impact factor: 12.767
Authors: Huldrych F Günthard; Judith A Aberg; Joseph J Eron; Jennifer F Hoy; Amalio Telenti; Constance A Benson; David M Burger; Pedro Cahn; Joel E Gallant; Marshall J Glesby; Peter Reiss; Michael S Saag; David L Thomas; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 157.335